Tag: NJ

Poster-Internet and Information Services

Passive Monitoring of Cognition Using a Smartphone Application in MS

Background: Cognitive impairment is one of the most common and debilitating symptoms of multiple sclerosis (MS). Traditional...

Read More

Poster-Disease-modifying Therapy

Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls

Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...

Read More

Poster-Epidemiology and Genetics

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More

Poster-Disease-modifying Therapy

Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis

INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...

Read More

Poster-Internet and Information Services

MS and COVID-19: A Webinar Series for Healthcare Providers

Background: MS is a complex disease that requires a well- educated workforce. The COVID-19 pandemic added to that complexity- from the lack...

Read More

Poster-Imaging

First Steps Towards Implementation of a Standardized MRI Protocol to Improve Care for People with MS in British Columbia

Background: Magnetic resonance imaging (MRI) is important in the diagnosis and monitoring of people with multiple sclerosis (MS). Using a...

Read More

Poster-Epidemiology and Genetics

Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Background: NARCRMS is a longitudinal registry studying the course of MS in the disease-modifying era. Objectives: To examine motor...

Read More

Poster-Disease-modifying Therapy

Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis

Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...

Read More

Poster-Disease-modifying Therapy

Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohn’s Disease

Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...

Read More

Poster-Disease-modifying Therapy

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...

Read More